

SPONSOR PROFILES



CSL is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our two businesses, CSL Behring and Seqirus – provides life-saving products to more than 60 countries and employs more than 22,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/Vita and follow us on [Twitter.com/CSL](https://twitter.com/CSL)



Shortening the distance
from lab to life.™

Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers' delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com.



Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. We provide scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow [@JNJInnovation](https://twitter.com/JNJInnovation).



Collaborating with organisations and communities within Australia and across the world, Deakin aims to provide better and more accessible individual educational outcomes and work with communities to positively contribute to growth and sustainability.

Our world-class research capabilities and facilities solve real problems – from health to business - in new ways, strengthening and streamlining pathways for commercial research and technologies that can change lives.

Deakin has also lead the way for women in the workplace, where women make up 52% of our academic staff and 67% of our professional staff, all of whom contribute with enthusiasm, intelligence and dedication to every aspect of Deakin life.

Deakin University offers a personalised experience, enhanced by innovative digital engagement. We lead by creating opportunities to live and work in a connected and evolving world.



Hemideina is a hearing solutions company, focussed on improving treatment for moderate-to profound deafness, with the Hera Wireless Implant. Hemideina's disruptive solution, inspired by insect hearing systems, aims to remove lifestyle barriers and improve hearing outcomes for patients. As a female-founded company, we are proud supporters of the BioMelbourne Network and their support and encouragement of women in the biomedical sector, through their Connecting Women Lunch and the Women in Leadership Awards.



Brooker Consulting excels in appointing superior CEOs, Directors and senior managers for life science entities of all kinds. This includes the health, research and commercialisation sectors, as well as professional associations, universities and service providers. Call Jeremy Wurm on 03 9602 1666 or email career@brookerconsulting.com.au www.brookerconsulting.com.au



Minifab is a world-leading provider of custom designed and manufactured microfluidic based point-of-care diagnostic and life-science devices.

Minifab's internationally-renowned team of experts based in Australia, Europe and US have completed over 1000 projects with clients worldwide.

Minifab's ISO13485 and ISO9001 product development and manufacturing processes covers the entire spectrum, from converting early-stage product concepts and requirements into advanced prototypes through to full-scale, high volume manufacturing.

Minifab's delivers unique customised products for a diverse range of applications including: Molecular; immuno and cellular point-of-care diagnostics; sample preparation and process integration; organ-on-chip; implantable devices for medical products.

Minifab celebrates its diverse team of experts and is proud to be a supporting sponsor of the Connecting Women Lunch 2019.



Phillips Ormonde Fitzpatrick is a leading Australian intellectual property firm. Our professionals work with innovators at the cutting edge of advancements in science and technology. We embrace diversity and

proudly recognise women in leadership, and are delighted to be an inaugural sponsor of the BioMelbourne Women's luncheon.



Starpharma is a world leader in the development of dendrimer products for pharmaceutical and other, life science applications. Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale

polymer that is well suited to pharmaceutical and medical uses. Starpharma has built a deep portfolio of high value, dendrimer products and successful partnerships with global companies including Astra Zeneca and Mundipharma. Its two core portfolios: VivaGel® and DEP® drug delivery include multiple clinical candidates in oncology and a novel non-antibiotic treatment for BV, VivaGel® BV. The latter is already on market in Australia and licensed in 160 countries with international launches occurring in 2019.



The Walter and Eliza Hall Institute of Medical Research is one of Australia's leading biomedical research organisations, with a strong national and international reputation for performing highly influential basic and translational research.

With more than 1,100 staff and students, the Institute is addressing some of the major health challenges of our time, with a focus on cancer, infection, inflammation, immune disorders, development and ageing. We are at the forefront of research innovation, with a strong commitment to excellence and investment in research computing, advanced technologies and developing new medicines and diagnostics.

The Institute is organised around five themes; Cancer Research and Treatments; Infection, Inflammation and Immunity; Healthy Development and Ageing; New Medicines and Advanced Technologies and Computational Biology.

This Institute is committed to delivering long term improvements in treating and diagnosing diseases, with many national and international clinical trials underway based on research undertaken at the Institute.



Nucleus Network is Australia's only multi-site dedicated phase I clinical research organisation with phase I facilities located in Melbourne (80 beds) and Brisbane (62 beds). The phase I units are strategically co-located within the Alfred Hospital in Melbourne (approx. 800 bed tertiary teaching hospital) and within the Royal Brisbane and Women's Hospital (approx. 900 bed tertiary teaching hospital) in Brisbane. This combination also provides Nucleus Network with access to a combined population of 7.5million people.

Nucleus Network have extensive experience in the conduct of early phase study designs in healthy volunteers and patient populations. Established in 2004, Nucleus Network has conducted over 750 phase I clinical trials, with 90% of our clients being overseas (primarily the USA) pharmaceutical and biotech companies. Nucleus Network runs approximately 70 phase I studies per year, with approximately 30 of these being true first-in-human studies.

With over 65% of staff being female, Nucleus Network demonstrates an organisation supportive of gender equality and who clearly values the contribution and leadership of women in the life sciences industry. It is therefore a delight and honour to be sponsoring the 11th Annual Connecting Women Lunch of 2019.